Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Genitourinary Cancers Steering Committee Roster

The Genitourinary Cancers Steering Committee (GUSC) addresses the design, prioritization, and evaluation of concepts for phase 2, 2/3, and 3 clinical trials in genitourinary cancers. Committee activities help foster collaboration between groups and institutions engaged in conducting trials. The GUSC's membership comprises NCTN group representatives, community oncologists, Specialized Programs of Research Excellence (SPORE) representatives, biostatisticians, patient advocates, subject matter experts, and NCI staff.

 

Co-chairs

Jason Efstathiou, M.D., D.Phil.
Massachusetts General Hospital
Boston, MA

William Kevin Kelly, D.O.
Thomas Jefferson University
Philadelphia, PA

Daniel W. Lin M.D.
University of Washington
Seattle, WA

 

Members

Toni K. Choueiri, M.D.
Dana-Farber Cancer Institute
Boston, MA

Anthony Crispino
UsTOO Las Vegas
Las Vegas, NV 

Elie G. Dib., M.D., M.S. FACP
St. Joseph Mercy Hospital
Ypsilanti, MI

James J. Dignam, Ph.D.
University of Chicago
Chicago, IL

Jared Foster, Ph.D.
National Cancer Institute
Bethesda, MD

Matthew D. Galsky, M.D.
The Tisch Cancer Institute at Mount Sinai
New York, NY

Naomi B. Haas, M.D.
University of Pennsylvania School of Medicine
Philadelphia, PA

Susan Halabi, Ph.D.
Duke University Medical Center
Durham, NCI

Sebastien J. Hotte, M.D., M.Sc., FRCPC
McMaster University
Hamilton, ON, Canada

Wassim Kassouf, M.D., C.M., FRCSC
McGill University
Montréal, QC, Canada

Seth P. Lerner, M.D.
Baylor College of Medicine
Houston, TX

Ravi A. Madan, M.D.
National Cancer Institute
Bethesda, MD

Bhupinder Mann, M.B.B.S.
National Cancer Institute
Bethesda, MD

David T. Marshall, M.D., M.S.
Medical University of South Carolina NCORP
Charleston, SC

Margaret Mooney, M.D., M.B.A.
National Cancer Institute
Bethesda, MD

Paul L. Nguyen, M.D. 
Dana-Farber Cancer Institute 
Boston, MA

Daniel P. Petrylak, M.D.
Yale University
New Haven, CT

Susan C. Poteat
Patient Advocate
Dayton, OH

Jonathan R. Rosenberg, M.D.
Memorial Sloan Kettering Cancer Center
New York, NY

Matthew J. Schipper, Ph.D., M.S.
University of Michigan
Ann Arbor, MI

Daniel E. Spratt, M.D., Ph.D.
University Hospitals of Cleveland, Cleveland Medical Center
Cleveland, OH

Robert Svatek, M.D.
University of Texas Health Science Center San Antonio 
San Antonio, TX

Catherine M. Tangen, Dr.PH.
Fred Hutchinson Cancer Research Center
Seattle, WA

NCI CCCT Program Director

Abdul Tawab Amiri, Ph.D.
atawab@mail.nih.gov

 

  • Updated:
Email